Nossent Johannes, Raymond Warren, Isobel Keen Helen, Preen David, Inderjeeth Charles
Department of Rheumatology, Sir Charles Gairdner Hospital, Perth, Australia.
Rheumatology Group, School of Medicine, The University of Western Australia, Perth, Australia.
Rheumatology (Oxford). 2021 Dec 24;61(1):291-298. doi: 10.1093/rheumatology/keab312.
With sparse data available, we investigated mortality and risk factors in adults with IgA vasculitis (IgAV).
This was an observational population-based cohort study using state-wide linked longitudinal health data for hospitalized adults with IgAV (n = 267) and matched comparators (n = 1080) between 1980 and 2015. Charlson comorbidity index (CCI) and serious infections (SIs) were recorded over an extensive lookback period prior to diagnosis. Date and causes of death were extracted from the Western Australia Death Registry. Mortality rate (deaths/1000 person-years) ratios (MRRs) and hazard ratio (HR) for survival were assessed.
During 9.9 (9.8) years lookback patients with IgAV accrued higher CCI scores (2.60 vs 1.50, P < 0.001) and had higher risk of SI (OR = 8.4, P < 0.001), not fully explained by CCI scores. During 19 years' follow-up, the rate of death in patients with IgAV (n = 137) was higher than in comparators (n = 397) (MRR = 2.06, 95% CI: 1.70-2.50; P < 0.01) and the general population (standardized mortality rate ratio = 5.64, 95% CI: 4.25, 7.53; P < 0.001). Survival in IgAV was reduced at 5 (72.7 vs 89.7%) and 20 years (45.2% vs 65.6%) (both P < 0.05). CCI (HR = 1.88, 95% CI: 1.25, 2.73; P = 0.001), renal failure (HR = 1.48, 95% CI: 1.04, 2.22; P = 0.03) and prior SI (HR = 1.48, 95% CI: 1.01, 2.16; P = 0.04) were independent risk factors. Death from infections (5.8 vs 1.8%, P = 0.02) was significantly more frequent in patients with IgAV.
Premorbid comorbidity accrual appears increased in hospitalized patients with IgAV and predicts premature death. As comorbidity does not fully explain the increased risk of premorbid infections or the increased mortality due to infections in IgAV, prospective studies are needed.
鉴于可用数据稀少,我们对成人IgA血管炎(IgAV)患者的死亡率及危险因素展开了调查。
这是一项基于人群的观察性队列研究,利用1980年至2015年间全州范围内住院的IgAV成人患者(n = 267)及匹配对照者(n = 1080)的纵向健康数据进行关联分析。在诊断前的一段较长回顾期内记录Charlson合并症指数(CCI)和严重感染(SI)情况。从西澳大利亚死亡登记处提取死亡日期及原因。评估死亡率(死亡数/1000人年)比值(MRR)及生存的风险比(HR)。
在9.9(9.8)年的回顾期内,IgAV患者的CCI评分更高(2.60对1.50,P < 0.001),发生SI的风险更高(OR = 8.4,P < 0.001),CCI评分无法完全解释这一现象。在19年的随访期内,IgAV患者(n = 137)的死亡率高于对照者(n = 397)(MRR = 2.06,95%CI:1.70 - 2.50;P < 0.01)以及一般人群(标准化死亡率比值 = 5.64,95%CI:4.25,7.53;P < 0.001)。IgAV患者在5年(72.7%对89.7%)和20年(45.2%对65.6%)时的生存率均降低(均P < 0.05)。CCI(HR = 1.88,95%CI:1.25,2.73;P = 0.001)、肾衰竭(HR = 1.48,95%CI:1.04,2.22;P = 0.03)及既往SI(HR = 1.48,95%CI:1.01,2.16;P = 0.04)为独立危险因素。IgAV患者因感染导致的死亡明显更频繁(5.8%对1.8%,P = 0.02)。
住院的IgAV患者病前合并症似乎增加,并预示过早死亡。由于合并症无法完全解释IgAV患者病前感染风险增加或因感染导致的死亡率升高,因此需要开展前瞻性研究。